-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $65

Benzinga·05/21/2026 11:04:57
Listen to the news
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $53 to $65.